Author

J. Ariey-Bonnet

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 2 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 3 Assay:bulk RNA-seq· 2 Approach:deep learning· 2 Research Focus:drug response / drug discovery· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Organism:mouse· 1 Assay:proteomics· 1

Frequent Co-Authors

E. Pasquier· 2 shared M. Le Grand· 2 shared X. Morelli· 2 shared A. Daulat· 1 shared B. Mouysset· 1 shared C. Colin· 1 shared D. Braguer· 1 shared D. Figarella-Branger· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

E. Pasquier

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Combination drug screen targeting glioblastoma core vulnerabilities reveals pharmacological synergisms

J. Ariey-Bonnet, R. Berges, M.-P. Montero, B. Mouysset, P. Piris, K. Muller, G. Pinna, T. W. Failes, G. M. Arndt, N. Baeza-Kallee, C. Colin, O. Chinot, D. Braguer, X. Morelli, N. ANDRE, , E. Pasquier

This study identifies synergistic drug combinations for glioblastoma by screening core vulnerabilities and validating them in preclinical models.

eBioMedicine · Sep 1, 2023Peer-reviewedPharmacology & Toxicology

The serine/threonine kinase MINK1 directly regulates the function of promigratory proteins

A. Daulat, M. S. Wagner, S. Audebert, M. Kowalczewska, J. Ariey-Bonnet, P. Finetti, F. Bertucci, L. Camoin, J.-P. Borg

This study identifies MINK1 as a kinase that phosphorylates LL5β, a component of the PRICKLE1 complex, promoting cell migration in triple-negative breast cancer and associating with poor metastasis-free survival.

bioRxiv · Sep 2, 2021Cell Biology

In silico molecular target prediction unveils mebendazole as a potent MAPK14 inhibitor

J. Ariey-Bonnet, K. Carrasco, M. Le Grand, L. Hoffer, S. Betzi, M. Feracci, P. Tsvetkov, F. Devred, Y. Collette, X. Morelli, P. Ballester, E. Pasquier

This paper identifies mebendazole as a potent MAPK14 inhibitor through in silico target prediction and experimental validation, revealing its potential for repurposing in brain tumor treatment.

bioRxiv · May 18, 2020Pharmacology & Toxicology